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Methylene dianiline (DDM; 4,4'-diamin-
odiphenylmethane) is a primary aromatic
amine that is used extensively in a variety
ofindustrial synthetic processes. DDM is
an important intermediate in the produc-
tion of isocyanates and rigid polyurethane
foams and is a component ofepoxy hard-
ening agents. Because of its widespread
use and large-scale production, there is
potential for human exposure and intoxi-
cation. A mass intoxication occurred in
Epping, England, in the late 1960s. The
pathologic changes in exposed individuals
were limited primarily to the liver. Liver
biopsies revealed portal edema and in-
flammation with an abundant cellular
infiltrate composed of neutrophils,
eosinophils, and mononuclear cells (1).
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Few investigations of acute DDM-
induced hepatotoxicity in animals have
been reported. Schoental (2) described
the lesions associated with long-term
exposure of rats and mice to DDM.
These included liver tumors and hepatic
lesions consisting of focal midzonal and
portal necrosis with marked leukocytic
infiltrates. These findings were consistent
with the lesions described by Kopelman in
humans intoxicated with DDM (1).
Pludro et al. (3) carried out a rudimentary
evaluation of the acute and subacute toxi-
city of DDM in rats. Kanz and co-work-
ers (4) characterized the histologic lesions
associated with a high dose of DDM.
This study revealed early injury to bile
duct epithelium, necrosis of hepatic
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Figure 1. Dose-related liver injury after oral administration of methylene dianiline to rats. Results are
expressed as the means ± SE. Data were analyzed with a completely random ANOVA or a two-way
ANOVA, as appropriate. Comparisons between treatment means were carried out using the Tukey's Xo
test or the least significant difference test, as appropriate (6). The criterion for significance was p < 0.05.
(A) Serum alanine aminotransferase activity; (B) bile flow; (C) total serum bilirubin content; (D) serum y-
glutamyltransferase activity (E) liver weight to body weight ratio (N = 5-6). Error bars, when not present,
were too small to appear on the graph. *Significantly differentfrom control.
parenchymal cells, and altered secretion
ofbiliary constituents in rats.
In this study, we further characterized
the hepatotoxic effects ofDDM. Our aim
was to delineate the biochemical and histo-
logic changes associated with acute DDM
intoxication and to understand the dose
relatedness and development of DDM
hepatotoxicity in rats. In addition, we
investigated the possibility that the cyto-
chrome P450 monooxygenase system
(MO) is involved in DDM-induced liver
injury in vivo.
Male Sprague Dawley rats [CF: CD
(SD)BR; Charles River, Portage, MI]
weighing 175-300 g were fasted for 24 hr
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Figure 2. Photomicrographs of the livers of rats 24 hr after oral administration of 100 mg/kg methylene dianiline (0DM) or vehicle. (A) Photomicrograph of the
liver from a rat receiving corn oil. Note the normal portal tracts and periportal parenchyma. H&E, 129x. (B-D) Photomicrographs of livers from 0DM-treated ani-
mals. (B) Focus of hepatocellular necrosis extending segmentally from the portal tract and involving the midzonal parenchyma, 128x. (C) Neutrophil infiltration
(white arrow) and fibrin exudation (black arrow) within the necrotic hepatic parenchyma, 257x. (0) Periportal edema (arrow), neutrophil infiltration, and segmen-
tal necrotizing vasculitis ofthe portal vein (extending from Ato 8), 125x.
before and after receiving DDM. We
treated rats with one of several doses
(25-225 mg/kg) ofDDM (Aldrich Chem-
ical Co., Milwaukee, WI) or an equivalent
volume of corn oil per os. All doses were
administered in a 2 ml/kg volume. We
anesthetized the rats with sodium pento-
barbital (50 mg/kg, IP) 24 hr after treat-
ment and placed the rats on a heating pad
to maintain body temperature. We cannu-
lated the common bile duct as previously
described (5) and collected bile flow for 30
min. The rats were then exsanguinated,
and blood was collected for determination
of indices of liver injury. We quantified
total serum bilirubin concentration spec-
trophotometrically (Sigma kit 605-D,
Sigma Chemical Co., St. Louis, MO).
Gamma-glutamyl transferase (GGT) activ-
ity was determined spectrophotometrically
by monitoring the GGT-catalyzed forma-
tion ofp-nitroanilide from the substrate,
L-y-glutamyl-p-nitroanilide (Sigma kit
419-20). As a marker ofhepatic parenchy-
mal injury, we determined serum alanine
aminotransferase (ALT) activity via a
kinetic spectrophotometric assay (Sigma
kit 59-20).
Oral administration of DDM caused a
dose-dependent change in all markers of
liver injury (Fig. 1). The threshold for tox-
icity was between 25 and 75 mg/kg DDM.
DDM administration caused concomitant
changes in all markers of liver injury mea-
sured, including serum ALT, bile flow,
serum bilirubin concentration, GGT activ-
ity, and liver weight (Fig. 1). Pludro et al.
(3) reported that the oral LD50 ofDDM in
rats was 830 mg/kg. They found histolog-
ic changes in liver and changes in plasma
electrophoretic patterns after subacute
administration of DDM at a dose equal to
one-tenth of the LD50. Our findings are
consistent with theirs.
Liver sections from animals that re-
ceived DDM (100 mg/kg, per os) had mul-
tifocal lesions consisting of hepatocellular
necrosis with hemorrhage and moderate
Table 1. Histologic characterization of methylene dianiline (DDM)-induced liver injury
Time after Bile ductular Portal Parenchymal
DDM Bile duct neutrophil venous Hepatocellular neutrophil
(hr) necrosis Edema Fibrin infiltrate vasculitis necrosis Hemorrhage infiltrate
4 1.5 0.0 0.3 0.0 0.0 0.0 0.0 0.0
6 2.5 2.0 2.0 1.3 1.3 0.5 0.0 0.0
12 4.0 2.0 2.0 2.0 1.5 2.3 1.3 1.5
16 4.0 2.0 2.0 3.0 1.8 4.0 2.3 3.5
Animals received 100 mg/kg DDM, per os. At various times thereafter rats were killed and tissues were fixed in 10% buffered formalin, embedded in paraffin,
sectioned at 6 lIM, and stained with hematoxylin and eosin. Histologic changes were assessed from slides that were coded. The pathologist had no knowledge
of treatment groups. Liver sections were evaluated for relative severity of lesions present and scored on a 0-4 scale (0 = normal relative to controls, 4 = most
severe changes). Control livers demonstrated normal hepatocellular architecture and no pathologic changes. These livers were assigned 0 as an arbitrary
score. Three sections of liver from different lobes were evaluated per animal. Each value represents the mean score of3-5 animals.
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Figure 3. Development of acute methylene dianiline (DDM)-induced hepatotoxicity. Fasted ral
100 mg/kg DDM per os or an equivalent volume of corn oil. At 4-hr intervals after administratic
rats were anesthetized with sodium pentobarbital Blood was collected from the descending
serum was used for assessment of liver injury by determination of bilirubin concentration,
transferase (GGT) activity and alanine aminotransferase (ALT) activity. (A) Serum ALT activity;
GGT activity; (C) serum bilirubin concentration; (D) liver weight to body weight ratio. Values
means ±SEM (N= 4-6). Error bars, where not present, were too small to appear on the graph.
values comprise data from rats killed at various times after vehicle administration. *Significant
from control value (p < 0.05).
Table 2. Effect of P450 monooxygenase modifiers on methylene dianiline (DDM)-induced hepa
DDM
dose ALT Bile flow Bilirubin GGT
Pretreatment (mg/kg) (U/I) (jd/g liver/30 min) (g/dl) (U/
Saline 100 524 ±65 5.5 ±4.7 4.0±0.6 5.4±0.6 4.1
ABT 145*±26 26*±6.9 2.2*±0.6 2.8*±0.4 4.1
Saline 100 540±82 0.3±0.1 4.2±0.3 6.2±0.8 3.1
SKF-525A 507 ±63 5.2±3.1 4.1 ±0.3 4.6 ±0.8 3.1
Corn oil 50 279 ±57 27.3 ±6.1 0.6 ±0.2 5.6 ±0.9 3.
BNF 136*±31 30.9±3.4 0.4±0.1 2.8*±0.3 4.5
Saline 50 588±122 ND 3.0±0.7 6.6±1.0 3.1
Phenobarbital 88*±11 ND 0.1*±0.01 0.8*±0.2 3.'
Saline 100 823 ± 100 3.9 ±1.5 4.6±0.5 10.0 ±1.8 3.1
Phenobarbital 706 ± 138 7.0±4.5 3.2±0.7 8.2± 1.6 4.
Abbreviations: ALT, alanine aminotransferase; GGT, y-glutamyltransferase; LW/BW, liver wei
weight ratio; ABT, aminobenzotriazole; BNF, 1-napthoflavone; ND, not detected.
Two hours before administration of DDM (100 mg/kg in corn oil, per os), rats were treated
mg/kg SKF-525A (20 ml/kg in saline), Sigma Chemical Co., St. Louis, MO), 100 mg/kg ABT
saline), or an equal volume of saline vehicle. Twenty-four hours later rats were anesthetize
was assessed, serum was obtained for evaluation of biochemical markers of liver injury, an
tions for histologic evaluation were taken as described above. Phenobarbital (70 mg/kg in sa
l-naphthoflavone (80 mg/kg, IP as a suspension in corn oil, Sigma), or their respective vehicl
were administered daily for 3 days preceding administration of DDM (100 or 50 mg/kg, per o
four hours after DDM administration, rats were processed as described above. Values represe
SEM, n = 8-11. *Significantly differentfrom pretreatment controls (p <0.05).
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neutrophil infiltration (Fig. 2). The necro-
sis involved segments of periportal hepato-
cytes but did not surround portal tracts.
Frequently, the parenchymal insult ex-
tended into the midzonal regions ofhepatic
lobules. The lesions associated with the
portal triad consisted of bile ductular
necrosis, portal edema with fibrin exudate,
and neutrophil infiltration. A segmental
necrotizing vasculitis ofthe portal vein was
also evident. The earliest change identified
with the hepatotoxicity of DDM was bile
ductular necrosis, and histologic markers of
liver injury continued to increase in severity
over the course of 16 hr (Table 1). His-
tologic analysis of livers from animals
receiving corn oil vehicle demonstrated
normal hepatic histology with no apparent
lesions.
Several investigators have described the
distribution of histologic changes in liver
associated with DDM intoxication (1,2,4).
In rats and mice, the loss of parenchyma
appeared to be primarily midzonal (1,2) or
midzonal and periportal (4). Our observa-
| tions were generally similar to those report-
ed by these investigators. However, we
found that the parenchymal lesions ap-
ts received peared adjacent to portal regions and
on of DDM, extended into midzonal regions of the
Iaorta, and liver. The lesions did not appear to be
(g)utseruym strictly periportal in that they did not
represent encircle the portal areas. In addition, the
Zero-time lesions were not restricted to the midzonal
tly different areas ofthe liver lobule, and they varied in
distribution. Finally, we observed a
prominent necrotizing vasculitis, which has
not been reported previously. This event
occurs early and therefore might be impor-
tant to the mechanism ofaction ofDDM.
totoxicity Recently, Kanz and co-workers (4)
evaluated some of the early hepatic
changes associated with administration of
WI/BW a large dose (250 mg/kg) of DDM. An
1 ±0.09 early (30 min) increase in biliary protein
2±0.13 and decreases in bile salts and bilirubin
8±0.07 content in bile occurred. Elevations in
8±0.06 bile flow and bile glutathione content
were concurrent with these changes.
7±0.10 Changes in serum markers of hepatic
*±0.08 parenchymal injury and cholestasis were
apparent by 4-8 hr. Histologic evidence
9
±0.18 from the present study suggests that the
earliest lesion is probably biliary in nature
9±0.05 (Table 1), a finding consistent with the
7* ±0.1 results of Kanz and co-workers (4). The
ight to body onset of liver damage caused by DDM
appears to be somewhat delayed in expres-
P with 40 sion. Although subtle changes in the his-
(2 ml/kg in tologic appearance of the portal regions in
d, bile flow the liver are evident by 4-8 hr, the first
Id liver sec- significant changes in biochemical markers
iline, IP), or of liver injury do not occur until later les (2 mI/kg)
s). Twenty- (Fig. 3).
ent means The lesions of DDM intoxication have
common histologic features to those
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caused by another cholangiolitic hepato-
toxicant, a-naphthylisothiocyanate
(ANIT). Portal edema, biliary epithelial
injury, and inflammation occur in both
models. However, the histologic distribu-
tion oflesions caused by ANIT are almost
exclusively limited to periportal areas.
Moreover, a distinct hepatic vascular injury
has not been reported after ANIT adminis-
tration. DDM seems to cause a more
severe hepatic parenchymal lesion and gen-
erates a more marked inflammatory re-
sponse than ANIT.
In a preliminary report, Ansari and co-
workers (7) presented evidence suggesting
the presence ofmetabolites ofDDM in rat
urine. Kajbaf and co-workers (8) have
recently identified oxidized metabolites of
DDM from microsomal preparations of
rabbit liver. To gain insight to the role of
metabolism in DDM hepatotoxicity, ani-
mals were pretreated with various agents at
doses that have been shown to alter MO
activity and to influence hepatotoxicity of
agents that require bioactivation by this
enzyme system (9-12). Aminobenzotria-
zole (ABT), an inhibitor ofMO, was effec-
tive at ameliorating the hepatotoxic effects
of DDM, as demonstrated by attenuation
of all markers of injury evaluated (Table
2). However, the MO inhibitor SKF-
525A did not protect against DDM-
induced liver damage. The difference in
the results obtained when using ABT ver-
sus SKF-525A may reflect a difference in
the spectrum of cytochrome P450 iso-
zymes inhibited by the two agents (10,
12,13). It is plausible that SKF-525A did
not inhibit the specific isozyme that bioac-
tivates DDM, whereas ABT effectively
attenuated metabolic activation.
The effect of phenobarbital pretreat-
ment varied with the dose of DDM. At a
dose of DDM (100 mg/kg) that caused
maximal hepatotoxic effects (Fig. 1), pre-
treatment with phenobarbital had no effect
on any ofthe markers ofliver injury (Table
2). At a more moderate dose ofDDM (50
mg/kg), phenobarbital pretreatment atten-
uated the hepatotoxicity. This result is
generally consistent with the preliminary
results of Kanz et al. (14), who found that
toxic effects of a large dose of DDM were
only modestly influenced by phenobarbital
pretreatment, and protection was largely
restricted to extrahepatic effects of DDM.
We also evaluated the effect of pretreat-
ment with a second inducer ofMO activi-
ty, f3-napthoflavone (BNF). This agent
had a modest effect on DDM hepatotoxic-
ity (Table 2). Like phenobarbital, BNF
pretreatment did not affect the toxicity ofa
higher dose (100 mg/kg) of DDM. These
findings suggest that there is a cytochrome
P450-dependent detoxification pathway
for DDM. However, it should be noted
that phenobarbital has myriad effects, not
only on phase 1 MO metabolism but also
on other enzyme systems. Thus, the atten-
uation of DDM toxicity may reflect an
action on phase 1 metabolism ofDDM or
on other metabolic systems, such as phase
2 conjugating systems, which might con-
tribute to DDM hepatotoxicity.
Assuming that the various agents we
used act by influencing metabolism of
DDM by MO, the results are consistent
with the following hypothesis: DDM
requires metabolic activation for its toxici-
ty. This activation is carried out by an
isozyme ofcytochrome P450 that is inhib-
ited by ABT but not by SKF-525A. In
addition, there is a competing, P450-medi-
ated reaction that is important in the
detoxification of DDM. This competing
reaction is enhanced by phenobarbital pre-
treatment and to a lesser extent by BNF
pretreatment. At low DDM doses, the two
opposing pathways compete for DDM
substrate. Accordingly, an increase in the
detoxification pathway by phenobarbital or
BNF pretreatment leads to decreased for-
mation oftoxic metabolites by the compet-
ing bioactivation pathway. At higher
DDM doses, enough substrate is present to
saturate the bioactivation pathway irrespec-
tive of the action of the detoxification
pathway. There is precedent for the con-
cept ofcompeting, toxifying, and detoxify-
ing pathways for hepatotoxicants in the
cases ofacetaminophen and bromobenzene
(13,15). Clearly, further study, including
the identification of DDM metabolites in
the rat, is needed to test this hypothesis
completely.
In summary, our results indicate that
DDM causes dose- and time-related toxici-
ty classified as multifocal, cholangiolitic
hepatitis, the lesions of which are distrib-
uted in portal and midzonal regions of
liver lobules. The results with inducers
and inhibitors ofcytochrome P450 mono-
oxygenase suggest that DDM requires
metabolic activation for its toxicity. As a
histologic feature of DDM hepatotoxicity
is a marked inflammatory response, it
would be ofinterest to evaluate the role of
inflammatory cells and soluble mediators
in DDM-induced liver injury.
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